Mina Mawani is a practiced and dedicated not-for-profit executive. She is a resilient, collaborative leader with a bold vision to lead organizations from vision-to-strategy-to results.
Mina’s portfolio includes over 15 years of experience in non-profit, private sector, hospital, and government roles, including President and CEO of the Canadian Women’s Foundation, Chief Development Officer for CivicAction, and Chief Executive Officer of the Aga Khan Council for Canada.
Currently, Mina is the President and Chief Executive Officer of Crohn’s and Colitis Canada. She applies her passion and enthusiasm to the Crohn’s and colitis community and is deeply engaged with the issues that matter most to her constituents – finding cures and improving lives for the millions of Canadians affected by these chronic diseases.
In recognition of her remarkable achievements, involvement, and contributions to communities across Canada, Mina has received the ICCC Humanitarian of the Year award, the RBC Top 25 Canadian Immigrant Award, the Grant’s Desi Achievers Award, and was named one of Canada’s Top 100 Most Powerful Women by the Women’s Executive Network.
Mina is a highly sought after speaker and respected advocate, engaging both public and private sectors, nationally and internationally. She is a loving, devoted wife and mother of two.
Day 1: Oct 6, 2020
Day 2: Oct 7, 2020
The Patient perspective – Instil the Patients’ Voice into Your Market Access Strategy to Enhance Your Product’s Success
Involving patient groups has become a cornerstone to the success of new product launches. Advance the validity of your R&D results, RWE and your market access strategy by incorporating the patient voice from the earliest possible stage of development. Create a blueprint to:
- Initiate greater collaboration with patient groups earlier on to engage them within the boundaries of compliance
- Understand the benefits of involving patients in the trial design stage
- Gain early insight into how patients react to your product that can enhance your success throughout your development cycle, submission processes and beyond to patient support
Instil the patients’ voice into your R&D to advance your market access strategy
Day 3: Oct 8, 2020